Search research articles
Contact Us
Filters
Showing results (81-90 of 426) with videos related to
Page
of 43
Sort By:
Nature Reviews. Nephrology
|
March 4, 2015
Renal effects of targeted anticancer therapies
Camillo Porta, Laura Cosmai, Maurizio Gallieni, et al.
Clinical Genitourinary Cancer
|
November 14, 2013
Considerations for the design of future clinical trials in metastatic renal cell carcinoma
Bernard Escudier, Daniel Y C Heng, Arthur Smyth-Medina, et al.
Journal of Nephrology
|
January 5, 2020
Correction to: Vitamin K effects in human health: new insights beyond bone and cardiovascular health
Maria Fusaro, Maurizio Gallieni, Camillo Porta, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer
|
March 13, 2023
An update on Merkel cell carcinoma
Maria Chiara Sergi, Eleonora Lauricella, Camillo Porta, et al.
The Lancet. Oncology
|
December 2, 2021
RAMES study: is there really a role for VEGF inhibition in mesothelioma?
Camillo Porta, Valerio Nardone, Steven G Gray, et al.
Journal of Nephrology
|
December 21, 2019
Vitamin K effects in human health: new insights beyond bone and cardiovascular health
Maria Fusaro, Maurizio Gallieni, Camillo Porta, et al.
Acta Bio-Medica : Atenei Parmensis
|
July 1, 2022
Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era
Valeria Internò, Roberta Rudà, Maria Chiara Sergi, et al.
Future Oncology (London, England)
|
November 27, 2015
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions
Camillo Porta, Giampaolo Tortora, James M G Larkin, et al.
Future Oncology (London, England)
|
June 22, 2021
Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
Francesca Negri, Letizia Gnetti, Giuseppe Pedrazzi, et al.
Cancer Management and Research
|
October 22, 2021
Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors
Gaetano Pezzicoli, Elisabetta Filoni, Angela Gernone, et al.
Page
of 43
Search research articles
Search
Showing results (81-90 of 426) with videos related to
Sort By:
Page
of 43
Nature Reviews. Nephrology
|
March 4, 2015
Renal effects of targeted anticancer therapies
Camillo Porta, Laura Cosmai, Maurizio Gallieni, et al.
Clinical Genitourinary Cancer
|
November 14, 2013
Considerations for the design of future clinical trials in metastatic renal cell carcinoma
Bernard Escudier, Daniel Y C Heng, Arthur Smyth-Medina, et al.
Journal of Nephrology
|
January 5, 2020
Correction to: Vitamin K effects in human health: new insights beyond bone and cardiovascular health
Maria Fusaro, Maurizio Gallieni, Camillo Porta, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer
|
March 13, 2023
An update on Merkel cell carcinoma
Maria Chiara Sergi, Eleonora Lauricella, Camillo Porta, et al.
The Lancet. Oncology
|
December 2, 2021
RAMES study: is there really a role for VEGF inhibition in mesothelioma?
Camillo Porta, Valerio Nardone, Steven G Gray, et al.
Journal of Nephrology
|
December 21, 2019
Vitamin K effects in human health: new insights beyond bone and cardiovascular health
Maria Fusaro, Maurizio Gallieni, Camillo Porta, et al.
Acta Bio-Medica : Atenei Parmensis
|
July 1, 2022
Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era
Valeria Internò, Roberta Rudà, Maria Chiara Sergi, et al.
Future Oncology (London, England)
|
November 27, 2015
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions
Camillo Porta, Giampaolo Tortora, James M G Larkin, et al.
Future Oncology (London, England)
|
June 22, 2021
Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
Francesca Negri, Letizia Gnetti, Giuseppe Pedrazzi, et al.
Cancer Management and Research
|
October 22, 2021
Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors
Gaetano Pezzicoli, Elisabetta Filoni, Angela Gernone, et al.
Page
of 43